Building on clinical data from several single-agent immunotherapy clinical trials, and by engaging scientists with unique and complementary expertise from eight institutions and three industry partners, the BEAT-HIV Collaboratory’s central mission will be to develop and test innovative combined immunotherapy strategies to eradicate and/or permanently suppress HIV replication in the absence of ART.